Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

The Independent UK

Australia secures Moderna vaccine facility

Hundreds of millions of mRNA vaccines will be made in Australia as part of a multi-billion dollar agreement with pharmaceutical giant Moderna.

AAP

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Tribune News Service

Moderna will produce its mRNA vaccines in Australia from 2024, with final deal signed off

The plant will have the capacity to produce up to 100 million vaccine doses each year, for COVID-19 and for other diseases like the seasonal flu.

ABC News

Moderna says vaccine for kids under 6 generates strong immune response

"This interim analysis showed a robust neutralizing antibody response in both age groups."

Axios

Moderna says its low-dose COVID shots work for kids under 6

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Why Moderna Shares Are Trading Higher Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Benzinga

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

The Independent UK

COVID’s ‘silver lining’: Research breakthroughs for chronic disease, cancer and the common flu

The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases.

Tribune News Service

California could see coronavirus uptick this spring because of omicron subvariant BA.2

LOS ANGELES — Coronavirus cases are on the upswing worldwide, prompting some officials to warn that California could see increases this spring because of the omicron subvariant BA.2 even though cases so far have been modest.

Los Angeles Times

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Businessweek

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Asharq Al-Awsat

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Moderna seeks emergency authorisation for second Covid booster in US

Moderna is seeking emergency use authorisation from US regulators for its second dose of a Covid-19 vaccine booster shot.

Tribune News Service

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Axios

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

The Independent UK

Moderna seeks FDA authorization for 4th dose of COVID shot

Drugmaker Moderna has asked the Food and Drug Administration to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

1 … 29 30 31 32

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

347 stories

PFE

346 stories

Centers for Disease Control and Prevention

National Institutes of Health

82 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.